

## MenQuadfi™ (meningococcal [Groups A, C, Y, W] conjugate vaccine) – New drug approval

- On April 24, 2020, [Sanofi announced](#) the [FDA approval](#) of [MenQuadfi \(meningococcal \[Groups A, C, Y, W\] conjugate vaccine\)](#), for active immunization for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W, and Y.
  - MenQuadfi is indicated for use in individuals 2 years of age and older.
  - MenQuadfi does not prevent *N. meningitidis* serogroup B disease
- MenQuadfi is the only FDA-approved quadrivalent meningococcal vaccine indicated for persons 2 through 56 years of age and older.
- The effectiveness of MenQuadfi for primary vaccination was assessed in four studies, and for booster vaccination in one additional study in a total of nearly 5,000 patients 2 years of age and older. To infer effectiveness of MenQuadfi, immunogenicity was assessed using a serogroup-specific serum bactericidal assay with exogenous human complement (hSBA). The hSBA geometric mean titers (GMTs) and proportion of participants who achieved hSBA seroresponse were evaluated.
  - Non-inferiority of MenQuadfi seroresponse rates vs. those for comparator vaccines was demonstrated for all 4 serogroups in individuals 2 years of age and older who received a primary vaccination and in individuals 15 years of age and older who received a booster vaccination at least 4 years following a previous dose of a meningococcal (Groups A, C, W, Y) conjugate vaccine.
- MenQuadfi is contraindicated in patients with severe allergic reaction to any component of the vaccine, or after a previous dose of MenQuadfi or any other tetanus toxoid-containing vaccine.
- Warnings and precautions for MenQuadfi include management of acute allergic reactions; altered immunocompetence; syncope; Guillain-Barré syndrome; tetanus immunization; and limitations of vaccine effectiveness.
- The most common adverse reactions ( $\geq 10\%$ ) with MenQuadfi following a primary dose were injection site pain (injection site erythema and swelling were also reported for children 2 through 9 years of age), malaise, myalgia, and headache.
  - In adolescents and adults, rates of solicited adverse reactions following a booster dose were comparable to those observed following primary vaccination.
- MenQuadfi is administered as a single 0.5 mL injection intramuscularly. For the primary vaccination, individuals 2 years of age and older receive a single dose. For booster vaccination, a single dose of MenQuadfi may be administered to individuals 15 years of age and older who are at continued risk for meningococcal disease if at least 4 years have elapsed since a prior dose of meningococcal (Groups A, C, W, Y) conjugate vaccine.

- Sanofi plans to launch MenQuadfi in 2021. MenQuadfi will be available as a 0.5 mL solution in a single-dose vial.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.